We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Chromosome Instability Patterns Predict Tumor Drug Response

By LabMedica International staff writers
Posted on 16 Jun 2022

By analyzing the differences in the number of repetitions of sequences of DNA within cancerous tumors, genomic researchers characterized 17 different types of chromosomal instability, which could be used to predict tumor drug response and to aid in the identifying future drug targets. More...

Chromosomal instability (CIN) is a type of genomic instability in which chromosomes are unstable, such that either whole chromosomes or parts of chromosomes are duplicated or deleted. Chromosomal instability is a common feature of cancer, occurring in around 80% of tumors, researchers are only now beginning to understand exactly what types or patterns of instability are present in any given tumor.

To increase this understanding, investigators at the University of Cambridge (United Kingdom) and colleagues at the Spanish National Cancer Research Center (Madrid, Spain) evaluated the extent, diversity, and origin of CIN across 7,880 tumors representing 33 cancer types.

Results of this evaluation revealed 17 different types of chromosomal instability. These chromosomal instability signatures could be used to predict how tumors might respond to drugs, as well as aiding in the identification of future drug targets.

Senior author Dr. Florian Markowetz, senior group leader at the Cancer Research UK Cambridge Institute of the University of Cambridge, said, "The more complex the genetic changes that underlie a cancer, the more difficult they are to interpret and the more challenging it is to treat the tumor. This is tragically clear from the very low survival rates for cancers that arise as a result of chromosomal instability. Our discovery offers hope that we can turn things around, providing much more sophisticated and accurate treatments. We are now working hard to bring our technology to patients and develop it to a level where it can transform patients' lives."

The CIN study was published in the June 15, 2022, online edition of the journal Nature.

Related Links:
University of Cambridge 
Spanish National Cancer Research Center 

 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.